グルカゴン様ペプチド1（GLP-1）アゴニストの世界市場（2024年版）：タイプ別（Tirzepatide, Semaglutide, Dulaglutide, Others）、エンドユーズ別（2型糖尿病、NASH、肥満）、流通チャネル別、投与経路別、地域別、国別の分析：市場インサイトと予測（2020-2030年）

Global Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type (Tirzepatide, Semaglutide, Dulaglutide, Others), End-Use (Type 2 Diabetes, NASH, Obesity), By Distribution Channel, By Route of Administration, By Region, By Country: Market Insights and Forecast (2020-2030)

エグゼクティブ・サマリーこの調査レポートはグルカゴン様ペプチド1（GLP-1）アゴニストの世界市場（2024年版）を分析・予測したAzoth Analyticsの市場調査報告書です、その他のタイプ）、流通チャネル別（... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2024年2月1日	US$2,450 シングルユーザライセンスライセンス・価格情報注文方法はこちら	250	英語

サマリー

エグゼクティブ・サマリー

この調査レポートはグルカゴン様ペプチド1（GLP-1）アゴニストの世界市場（2024年版）を分析・予測したAzoth Analyticsの市場調査報告書です、その他のタイプ）、流通チャネル別（クリニック、外来手術センター、病院）、投与経路別（経口、非経口）、エンドユース別（2型糖尿病、NASH、肥満）、2020-2023年の過去期間、2023年の予測、2024-2030年の予測期間。

この調査レポートは、地域（米州、欧州、アジア太平洋、中東・アフリカ）と国（米国、カナダ、英国、ドイツ、フランス、イタリア、インド、中国、日本、韓国）の詳細な分析をカバーしています。さらに、この調査レポートは、市場規模、年間成長＆潜在能力分析、市場プレイヤーの競争調査、投資機会、需要予測などのデータを提示しています。この調査レポートは、成長指標、阻害要因、需給リスク、その他の重要な統計、市場の進化に関連する現在および将来の市場動向の完全な評価も行っています。

グルカゴン様ペプチド1（GLP-1）アゴニストの世界市場は、2020-2023年にCAGR 20.6%の成長を示しました。2022年の市場規模は187億5,000万米ドルで、2030年には1,335億米ドルに達する見込みです。GLP-1アゴニストの需要は世界的に拡大しており、先進地域と発展途上地域の両方が市場成長に貢献している。新興国ではT2DMの有病率が上昇しており、GLP-1作動薬治療を含む効果的な糖尿病管理戦略の必要性が高まっています。同市場には、短時間作用型および長時間作用型のさまざまなGLP-1作動薬があり、医療従事者および患者にさまざまな選択肢を提供している。これらの薬剤は皮下注射または場合によっては経口投与される。

GLP-1作動薬はT2DM患者の血糖コントロール改善に有効であることが知られており、しばしばHbA1c値や空腹時血糖値の低下をもたらす。さらに，これらの薬剤は体重減少を伴うので，肥満の糖尿病患者には特に有益である。

いくつかのGLP-1作動薬は、臨床試験において、心臓発作、脳卒中、心血管死などの主要な有害心血管イベント（MACE）を減少させるなど、心血管系に有益であることが示されている。これらの知見は、T2DMを有し、心血管疾患（CVD）が確立している、あるいは心血管リスクが高い患者におけるGLP-1作動薬の採用拡大に寄与している。

GLP-1作動薬は主に皮下注射で投与されるが、患者の服薬アドヒアランスと利便性を向上させるため、経口製剤や週1回注射などの代替投与法の開発が進められている。これらの技術革新は、治療アドヒアランスに対する潜在的な障壁に対処し、患者の満足度を高めることを目的としています。

レポートの範囲

- このレポートは世界のグルカゴン様ペプチド1（GLP-1）作動薬市場を金額（百万米ドル）別に分析しています。

- 本レポートでは、世界のグルカゴン様ペプチド1（GLP-1）アゴニスト市場の過去期間である2020-2023年、推定期間である2023年、予測期間である2024-2030年の分析を紹介します。

- グルカゴン様ペプチド1（GLP-1）アゴニストの世界市場をタイプ別（Tirzepatide、Semaglutide、Dulaglutide、その他のタイプ）に分析しています。

- グルカゴン様ペプチド1（GLP-1）アゴニストの世界市場を流通チャネル別（クリニック、外来手術センター、病院）に分析しています。

- グルカゴン様ペプチド1（GLP-1）アゴニストの世界市場を投与経路別（経口、非経口）に分析しています。

- グルカゴン様ペプチド1（GLP-1）アゴニストの世界市場をエンドユーザー別（2型糖尿病、NASH、肥満症）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、タイプ別、流通チャネル別、投与経路別、エンドユーズ別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 本レポートでは、競合の動向、戦略、M&A、新製品開発を追跡しています。本レポートで分析している企業は、イーライリリー・アンド・カンパニー、ファイザー、サノフィ、アストラゼネカPLC、ベーリンガーインゲルハイム、ノボノルディスクなどです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

3. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

3.1 Impact Analysis of Macro Economic Factors on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.2 Pipeline Analysis of GLP-1 Agonist Market

3.3 Global Obesity Statistics 2022, in Millions

3.4 Diabetes Statistics

3.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Dashboard

3.6 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million)

3.7 Impact of COVID-19 on Glucagon-Like Peptide 1 (GLP-1) Agonist Market

3.8 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Type

3.8.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type Overview

3.8.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR)

3.8.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR)

3.9 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

3.9.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

3.9.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

3.9.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

3.9.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

3.10 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

3.10.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

3.10.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

3.10.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

3.11 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

3.11.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

3.11.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

3.11.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

3.11.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

4. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Regional Analysis

4.1 Regional Coverage of the Study

4.2 Regional Snapshot

5. Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

5.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

5.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

5.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

5.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

5.5 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

5.6 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

5.6.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

5.6.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

5.6.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

5.6.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

5.7 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

5.7.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

5.7.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

5.7.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

5.8 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

5.8.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

5.8.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

5.8.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

5.8.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

5.9 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

5.9.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

5.9.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.2.1 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.2.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.2.3 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.3.1 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.3.2 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.3.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

5.9.4 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

5.9.4.1 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

5.9.4.2 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

5.9.4.3 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6. Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

6.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

6.6 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

6.6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

6.6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

6.6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

6.6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

6.7 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

6.7.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

6.7.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

6.7.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

6.8 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

6.8.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

6.8.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

6.8.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

6.8.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

6.9 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

6.9.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

6.9.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.2.1 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.2.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.2.3 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.3.1 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.3.2 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.3.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.4 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.4.1 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.4.2 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.4.3 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.5 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.5.1 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.5.2 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.5.3 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

6.9.6 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

6.9.6.1 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6.9.6.2 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

6.9.6.3 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7. Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

7.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

7.5 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

7.6 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

7.6.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

7.6.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

7.6.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

7.6.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

7.7 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

7.7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

7.7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

7.7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

7.8 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

7.8.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

7.8.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

7.8.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

7.8.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

7.9 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country

7.9.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview

7.9.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.2.1 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.2.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.2.3 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.3.1 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.3.2 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.3.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.4 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.4.1 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.4.2 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.4.3 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.5 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.5.1 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.5.2 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.5.3 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7.9.6 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)

7.9.6.1 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

7.9.6.2 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration

7.9.6.3 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

8. Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot

8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)

8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors

8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment

8.5 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics

8.6 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel

8.6.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview

8.6.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)

8.6.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)

8.6.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)

8.7 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration

8.7.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview

8.7.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)

8.7.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)

8.8 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use

8.8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview

8.8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)

8.8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)

8.8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter’s Five Forces Model

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Share Analysis of Glucagon-Like Peptide 1 (GLP-1) Agonist Market

11.3 Company Profiles

11.3.1 Eli Lilly and Company

11.3.2 Pfizer

11.3.3 Sanofi

11.3.4 AstraZeneca PLC

11.3.5 Boehringer Ingelheim

11.3.6 Novo Nordisk

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market (2024 Edition)” which provides a complete analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist industry in terms of market segmentation By Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types), By Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals), By Route of Administration (Oral, and Parenteral) By End-Use (Type 2 Diabetes, NASH, and Obesity), for the historical period of 2020-2023, the estimates of 2023 and the forecast period of 2024-2030.

The research report covers a detailed analysis of the Region (Americas, Europe, Asia Pacific, and Middle East and Africa) and Countries (United States, Canada, UK, Germany, France, Italy, India, China, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market showcased growth at a CAGR of 20.6% during 2020-2023. The market was valued at USD 18.75 Billion in 2022 which is expected to reach USD 133.5 Billion in 2030. The demand for GLP-1 agonists extends globally, with both developed and developing regions contributing to market growth. Emerging economies are witnessing a rising prevalence of T2DM, driving the need for effective diabetes management strategies, including GLP-1 agonist therapies. The market includes a variety of GLP-1 agonist drugs, both short-acting and long-acting formulations, offering different options for healthcare providers and patients. These drugs are administered via subcutaneous injection or, in some cases, orally.

GLP-1 agonists are known for their efficacy in improving glycemic control in patients with T2DM, often leading to reductions in HbA1c levels and fasting plasma glucose levels. Additionally, these drugs are associated with weight loss, making them particularly beneficial for obese individuals with diabetes.

Several GLP-1 agonists have demonstrated cardiovascular benefits in clinical trials, including reductions in major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular death. These findings have contributed to the growing adoption of GLP-1 agonists in patients with T2DM and established cardiovascular disease (CVD) or high cardiovascular risk.

While GLP-1 agonists are primarily administered via subcutaneous injections, efforts are underway to develop alternative delivery methods, such as oral formulations and once-weekly injections, to improve patient adherence and convenience. These innovations aim to address potential barriers to treatment adherence and enhance patient satisfaction.

Scope of the Report

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market by Value (USD Million).

• The report presents the analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market for the historical period of 2020-2023, the estimated year 2023, and the forecast period of 2024-2030.

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Route of Administration (Oral, and Parenteral).

• The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by End-Use (Type 2 Diabetes, NASH, and Obesity).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, By Distribution Channel, By Route of Administration & By End-Use.

• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Eli Lilly and Company, Pfizer, Sanofi, AstraZeneca PLC, Boehringer Ingelheim, and Novo Nordisk.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

Azoth Analytics社の医療・製薬分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?